LAS VEGAS, NV / ACCESSWIRE / April 14, 2016 / As Neutra Corp. (OTCQB: NTRR) works to deliver more and better products for cannabis patients and growers, the market for those products continues to expand rapidly around the world. According to a new white paper produced by the University of Sydney Business School and MCG Pharmaceuticals, Australians could consume up to 8,000 kg (17,636 lbs) of medical cannabis in the first year of legalization there--potentially generating $100 million at the industry's outset.
The research paper is the first of its kind on the Australian market. The Australian Parliament passed a measure legalizing medical cannabis in February. The figures were based on the sales data and trends in other nations where cannabis is prescribed and grown, such as the Netherlands, Canada and Israel.
8,000 kg of cannabis worth of demand will present significant challenges for Australia's nascent industry--particularly since consumer trends in top markets around the globe have shifted toward cannabis grown without the use of potentially hazardous chemicals, making cannabis treatments safer, more discrete and more reliable for patients.
NTRR is hard at work marketing and promoting new, antimicrobial alternatives to harsh chemicals used in cannabis farms. In 2016, NTRR plans to continue to source out solutions for cannabis producers and consumers alike as the regulated cannabis industry continues to swell in the United States, Canada and beyond. For more information on the company's mission, please visit http://neutrainc.com/investors.
About Neutra Corp.
As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.
By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII). For investing information and performance data, please visit www.neutrainc.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com
SOURCE: Neutra Corp.
ReleaseID: 438816
